EMA/PE/0000182362 - paediatric investigation plan

tildrakizumab

Key facts

• Invented name:
  Ilumetri
• Active substance:
  tildrakizumab
• Therapeutic area:
  Skin and subcutaneous tissue disorders
• Decision number:
  EMA/PE/0000182362
• PIP number:
  EMA/PE/0000182362
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of psoriasis
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  15/11/2024
• Compliance check done:
  Nein

Decision

EMA/PE/0000182362: EMA decision of 14 November 2024 on the acceptance of a modification of an agreed paediatric investigation plan for tildrakizumab (Ilumetri)

Adopted Reference Number: EMADOC-1700519818-1760793